While Q2 2026 generated positive free cash flow of $4.1 million, this follows a historical pattern of severe cash burn, and the operating cash flow conversion of 31% relative to net income suggests limited cash generation from the new revenue stream.
Omeros Corporation (OMER) cash flow statement — 19-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 |
|---|
| Cash from Operations | -68.67M | -116.09M | -148.8M | 74.73M | -86.48M | -109.72M | -100.09M | -60.07M | -103.74M | -36.23M | -51.5M | -65.21M | -58.04M | -29.7M | -34.55M | -25.67M | -14.5M | -19.03M | -19.67M | -14.31M |
| Operating CF Margin % | - | - | - | - | - | - | - | -53.73% | -347.32% | -55.88% | -123.76% | -482.71% | -10768.83% | -1855.94% | -573.75% | -567.37% | -688.93% | -1317.66% | -1681.45% | -744.36% |
| Operating CF Growth % | 183.33% | 21.98% | -299.13% | 186.41% | 21.18% | -9.63% | -66.61% | 42.09% | -186.35% | 29.66% | 21.02% | -12.34% | -95.47% | 14.05% | -34.61% | -77% | 23.78% | 3.28% | -37.44% | - |
| Net Income | 124.83M | -3.35M | -156.81M | -117.81M | -182.03M | -191.55M | -138.06M | -84.49M | -126.76M | -53.48M | -66.75M | -75.1M | -73.67M | -39.8M | -38.44M | -28.55M | -29.25M | -21.09M | -23.83M | -23.09M |
| Depreciation & Amortization | 907K | 964K | 950K | 920K | 952K | 1.39M | 1.62M | 1.79M | 962K | 551K | 300K | 209K | 326K | 302K | 320K | 435K | 472K | 451K | 434K | 375K |
| Stock-Based Compensation | 5.29M | 8.19M | 10.49M | 11.65M | 0 | 0 | 14.93M | 13.79M | 11.71M | 12.69M | 13.58M | 9.58M | 8.92M | 6.25M | 4.28M | 1.93M | 2.18M | 1.49M | 2.31M | 6.06M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | -12.01M | 0 | -12.93M | 0 | 5.59M | 1.31M | 854K | 41K | 511K | 28.55M | 329K | 34K | 294K | -145K |
| Other Non-Cash Items | -216.82M | -155.62M | -33.17M | -67.45M | 213.56M | 94.54M | 25.86M | 9.23M | 18.98M | 4.19M | 1.98M | 1.04M | 738K | 502K | 354K | -28.19M | 174K | -595K | 2M | 503K |
| Working Capital Changes | 21.93M | 33.72M | 29.74M | 247.42M | -118.97M | -14.11M | 7.58M | -394K | 4.29M | -172K | -6.21M | -2.26M | 4.79M | 3M | -1.57M | 164K | 11.6M | 678K | -892K | 1.99M |
| Change in Receivables | 25.94M | 30.45M | 40.01M | 245.72M | -175.07M | -34.31M | 31.34M | -12.37M | -6.17M | -5.11M | -5.52M | -6.13M | -13K | 1.55K | -1.06K | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | -842K | 0 | 0 | 0 | 0 | 0 | -208K | -1.06M | 355K | 685K | -656K | 96K | -568K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.24M | 0 | 0 | 0 | -10.66M | 14.64M | -19.74M | 13.28M | 10.54M | 9.52M | -319K | 4.2M | 5.46M | -1.17M | 957K | 1.46M | 1.46M | -140K | 0 | 0 |
| Cash from Investing | 136.82M | 164.52M | 82.22M | 27.45M | -127.56M | 193.71M | -67.03M | -3.4M | 25.15M | -37.6M | -16.34M | -20.61M | 6.16M | 7.91M | -907K | 16.91M | 19.92M | -52.4M | 10.57M | -6.09M |
| Capital Expenditures | 239.94M | -65K | -165K | -426K | -113K | -277K | -283K | -334K | -567K | -350K | -126K | -240K | -28K | -204K | -642K | -1.24M | -8.44M | -279K | -164K | -534K |
| CapEx % of Revenue | 624.5% | - | - | - | - | - | - | 0.3% | 1.9% | 0.54% | 0.3% | 1.78% | 5.19% | 12.75% | 10.66% | 27.43% | 400.86% | 19.32% | 14.02% | 27.77% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 125.99M | 0 | 3.07K | 0 | 0 | 126K | 240K | 28K | 0 | 0 | 33K | 0 | 76K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 240M | 0 | 0 | 0 | 0 | 0 | -3.07K | 25.72K | -37.25K | -126K | -240K | -28K | 8.11K | -265 | -33K | 7.63M | -76K | 0 | 0 |
| Cash from Financing | -68.06M | -42.17M | 62.88M | -106.08M | 124.25M | 6.32M | 174.53M | 60.7M | 81.05M | 75M | 68.7M | 86.83M | 50.86M | 21.65M | 32.97M | 9.49M | -2.96M | 59.52M | 15.91M | 2.93M |
| Debt Issued (Net) | -99.15M | -89.16M | -41.34M | -101.58M | 123.83M | -1.82M | 98.2M | -1.14M | 109.62M | -431K | 24.16M | 15.33M | 11.48M | 0 | 298K | 8.89M | -3.26M | -4.12M | 15.87M | -1M |
| Equity Issued (Net) | 45.69M | 46.99M | -11.85M | -4.65M | 415K | 8.38M | 93.67M | 54.24M | 0 | 63.66M | 38.04M | 79.08M | 37.75M | 20.99M | 32.31M | 0 | 0 | 63.64M | 40K | 3.7M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -5.77M | 0 | -11.85M | -4.65M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.15M | 0 | -48K | 0 | 0 |
| Other Financing | -14.61M | 0 | 116.07M | 150K | 0 | -241K | -17.34M | 7.6M | -28.57M | 11.77M | 6.5M | -7.58M | 1.62M | 662K | 369K | 595K | 299K | 0 | 0 | 239K |
| Net Change in Cash | 84K | 6.26M | -3.71M | -3.9M | -89.8M | 90.31M | 7.42M | -2.78M | 2.47M | 1.17M | 859K | 1.01M | -1.03M | -136K | -2.48M | 727K | 2.46M | -11.91M | 6.8M | -17.48M |
| Free Cash Flow | -68.73M | -116.16M | -148.97M | 74.3M | -86.6M | -110M | -100.37M | -60.41M | -104.3M | -36.58M | -51.63M | -65.45M | -58.07M | -29.9M | -35.19M | -26.91M | -22.94M | -19.31M | -19.84M | -14.85M |
| FCF Margin % | -178.88% | - | - | - | - | - | - | -54.03% | -349.22% | -56.42% | -124.06% | -484.48% | -10774.03% | -1868.69% | -584.41% | -594.81% | -1089.79% | -1336.98% | -1695.47% | -772.13% |
| FCF Growth % | 42.2% | 22.02% | -300.5% | 185.8% | 21.28% | -9.59% | -66.15% | 42.09% | -185.16% | 29.16% | 21.11% | -12.7% | -94.23% | 15.04% | -30.79% | -17.3% | -18.82% | 2.68% | -33.6% | - |
| FCF per Share | -0.77 | -1.83 | -2.56 | 1.18 | -1.38 | -1.76 | -1.76 | -1.22 | -2.15 | -0.80 | -1.28 | -1.74 | -1.75 | -1.05 | -1.46 | -1.21 | -1.07 | -2.67 | -1.85 | -1.04 |
| FCF Conversion (FCF/Net Income) | -0.55x | 34.65x | 0.95x | -0.63x | -1.82x | 0.98x | 0.72x | 0.71x | 0.82x | 0.68x | 0.77x | 0.87x | 0.79x | 0.75x | 0.90x | 0.90x | 0.50x | 0.90x | 0.83x | 0.62x |
| Interest Paid | 11.16M | 35.42M | 35.69M | 29.92M | 0 | 0 | 11.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | -86K | 153K | 165K | 3.29M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying OMER stock.
Omeros Corporation (OMER) generated $-116.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Omeros Corporation (OMER) reported negative free cash flow of $116.2M in 2025, indicating capital requirements exceeded cash from operations.
Omeros Corporation (OMER) spent $0.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Critical liquidity and regulatory risk
Metrics are mathematically derived from official filings.
Earnings Quality Divergence in Launch Quarter
The Q2 2026 operating cash flow of $4.1 million represents only 31% of the $13.2 million net income, suggesting that a significant portion of the reported profit is non-cash or tied to working capital movements rather than immediate cash generation.
This conversion ratio is a stark reversal from the prior four quarters, where operating cash flow consistently exceeded net income, indicating that the new revenue stream from YARTEMLEA may be subject to different collection dynamics or accrual patterns. The divergence warrants close monitoring, as the sustainability of the cash flow profile depends on the quality of this new commercial revenue, not just its accounting recognition.
FCF Inflection Masked by Historical Burn
Omeros generated positive free cash flow of $4.1 million in Q2 2026, its first positive quarter in over two years, yet this follows a cumulative free cash flow deficit exceeding $250 million over the prior eight quarters.
The positive FCF is a critical milestone, but its magnitude is modest relative to the company's historical cash burn and the $9.66 million cash balance reported. The trajectory is now dependent on the ramp of YARTEMLEA royalties and the management of R&D spend for late-stage programs like narsoplimab and OMS906, making the positive quarter a potential inflection point rather than a confirmed trend.
Working Capital Swings Drive Cash Volatility
Working capital changes have been the primary driver of operating cash flow volatility, with a $3.3 million use of cash in Q2 2026 following a $5.2 million use in Q1, indicating potential challenges in converting new revenue to cash.
The pattern of working capital consuming cash in recent quarters, despite the emergence of revenue, suggests that receivables may be building or that the company is extending terms to support the YARTEMLEA launch. This dynamic is critical to watch, as persistent working capital drag could undermine the cash flow benefits of the new revenue stream and accelerate the need for external financing.
Capital Deployment Shifts to Share Repurchases
In Q2 2026, Omeros deployed $1.6 million for share repurchases, marking a shift from the prior pattern of using cash primarily for operations and minimal capital expenditures.
This repurchase activity, while small in absolute terms, is notable given the company's precarious $9.66 million cash position and history of dilutive financing. It may signal management's confidence in the new revenue trajectory, but it also raises questions about capital allocation priorities when the cash runway is measured in quarters, not years.
Cash Flow Statement Obscures True Burn Rate
The reported $4.1 million operating cash flow in Q2 2026 is likely overstated as a sustainable figure, as it excludes the full cash impact of ongoing R&D for narsoplimab and OMS906, which are capitalized or accrued.
The cash flow statement does not fully capture the future cash obligations tied to the company's clinical pipeline, which represent the core of its operational strategy. Furthermore, the treatment of the Omidria royalty stream and potential milestone payments can create timing differences between cash receipt and revenue recognition, obscuring the true underlying cash generation capability of the business.